Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Retinal immune cell gateway may unlock targeted uveitis treatments

As part of an effort to understand the molecules and mechanisms that regulate transendothelial migration in different vascular beds of the body, researchers focused on the blood vessels of the retina, part of the blood-brain barrier.

8 Sep 2026

New biologic therapy significantly reduces COPD flare-ups in trials

Two international clinical trials led in part by researchers at the University of Pittsburgh School of Medicine found that the investigational biologic therapy tozorakimab significantly reduced chronic obstructive pulmonary disease (COPD) flare-ups among patients already receiving standard treatment for the disease compared to patients only receiving standard treatment.

8 Sep 2026

Microscopic peptide droplets reduce colorectal tumor growth in mice

Scientists from Nanyang Technological University, Singapore (NTU Singapore) have developed microscopic peptide droplets that deliver large amounts of gene-silencing molecules into cancer and immune cells, reducing the growth of hard-to-treat colorectal tumours by about 67 per cent in mice.

3 Sep 2026

Investigational anti-interleukin-6 monoclonal antibody achieves durable inflammatory biomarker reductions

The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in inflammation-related biomarkers through six months in patients with chronic kidney disease and elevated inflammatory risk associated with heart disease.

29 Aug 2026

Pacibekitug safely reduces inflammatory biomarkers in kidney disease patients

The interleukin-6 (IL-6) antibody, pacibekitug, produced sustained reductions in inflammatory biomarkers in patients with chronic kidney disease at high inflammatory risk, according to results from the phase II TRANQUILITY trial presented in a Hot Line session today at ESC Congress 2026.

29 Aug 2026

New combination therapy could permanently clear HIV in newborns

Every year, more than 120,000 newborns worldwide contract HIV, a global health burden that requires lifelong treatment for millions of people - assuming they have access and can afford it.

10 Aug 2026

AI tool aims to accelerate Alzheimer's treatment through faster referrals

Vanderbilt Health researchers have received a grant from Eli Lilly and Company, a multinational pharmaceutical company headquartered in Indianapolis, to build an artificial intelligence (AI) tool within the electronic health record system (EHR) to get patients with Alzheimer's disease to treatment faster.

5 Aug 2026

Phase 3 clinical trial enrolls first platinum-resistant ovarian cancer patient

The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3132/BEHOLD-Ovarian01 (NCT07286266), a global Phase 3 clinical trial titled A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants with Platinum-resistant Ovarian Cancer.

27 Jul 2026

AbbVie Strengthens Immunology Leadership with $10.9 Billion Apogee Therapeutics Acquisition

AbbVie's strategic acquisition of Apogee Therapeutics highlights its commitment to advancing immunology and developing next-generation treatments for patients.

From 10th Dermatology Drug Development Summit 15 Jul 2026

WHO launches PARTNERS clinical trial for Bundibugyo virus treatments

In a major international effort to evaluate potential treatments for Ebola disease due to Bundibugyo virus (BVD), the PARTNERS clinical trial has opened enrolment today for patients in the Democratic Republic of the Congo.

3 Jul 2026

Monoclonal antibody shows promise for treating acute respiratory distress syndrome

Doctors have few options for patients who develop a life-threatening lung condition called acute respiratory distress syndrome, or ARDS.

30 Jun 2026

Study explains how leukemia creates inflammatory lung environments

Acute myeloid leukemia (AML) does more than infiltrate the lungs: it also transforms lung tissue to create an inflammatory environment that promotes the expansion of tumor cells and impairs respiratory function.

30 Jun 2026

Heart tissue repair drug may also help repair and regenerate damaged kidney tissues

A drug previously developed at UCLA to help heart tissue repair itself after a heart attack might also help kidney tissue repair and regenerate, researchers have found.

16 Jun 2026

Study identifies genetic marker associated with severe IBD

In the largest genetic study of inflammatory bowel disease (IBD) traits to date, researchers have identified a genetic marker that is associated with more severe ulcerative colitis and Crohn's disease – the major forms of IBD.

15 Jun 2026

Apitegromab helps tirzepatide users lose fat while preserving lean mass

A phase 2 trial found that apitegromab plus tirzepatide reduced lean body mass loss by 1.9 kg compared with tirzepatide plus placebo after 24 weeks, while overall weight loss remained similar.

9 Jun 2026

Maternal vaccination provides protection against RSV-associated hospitalization in early infancy

A study led by researchers at the University of Pittsburgh and UPMC published today in JAMA Network Open, a peer-reviewed journal of the American Medical Association, found that vaccination against respiratory syncytial virus (RSV) during pregnancy reduced the risk of hospitalization in young infants by nearly 70%.

5 Jun 2026

Higher-dose ocrelizumab depletes more B cells but does not slow MS progression

Higher-dose ocrelizumab produced greater peripheral B-cell depletion than the approved 600 mg regimen in two phase 3b trials of relapsing and primary progressive multiple sclerosis. However, the higher doses did not significantly delay disability progression, supporting the 600 mg dose as the current standard regimen with a favorable benefit-risk profile.

31 May 2026

WHO prioritizes candidate vaccines and therapeutics for Bundibugyo virus

In response to the current outbreak of Ebola disease caused by Bundibugyo virus occurring in the Democratic Republic of the Congo, with cases also reported in Uganda, WHO convened several of its expert and advisory groups.

29 May 2026

Artificial intelligence-based tool could improve multiple myeloma treatment decisions

An artificial intelligence-based tool may help physicians determine which newly diagnosed multiple myeloma patients are most likely to benefit from specific therapies, including immunotherapy and stem cell transplantation.

21 May 2026

Phase two clinical trial demonstrates dramatic mobility gains in children with severe fibrous dysplasia

Fibrous dysplasia is a rare skeletal disorder in which normal bone is gradually replaced by weak fibro-osseous tissue, leading to fractures, pain, deformities, and severe mobility impairment. In many patients, diseased bone tissue produces excessive amounts of fibroblast growth factor-23 (FGF23), a hormone that causes phosphate loss through the kidneys.

21 May 2026